JHM Biopharma key facts
as of Oct 2026- Provider and developer of biological proteins used as medications.
- JHM Biopharma is valued at approximately $159.7M as of Oct 2026 (last reported valuation).
- It has raised $84.8M; the latest was Early Stage VC in May 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, SDIC Unity Capital, Shanghai Guofang Private Equity Fund Management Company, 3E Bioventures Capital, China Capital Zhongcai Fund Management — 13 tracked in total.
- Status: Privately Held (backing).
JHM Biopharma's last reported valuation, May 2024. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch JHM Biopharma: the Monday email on marks, rounds and moves
JHM Biopharma funding rounds
No funding rounds for JHM Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs JHM Biopharma
13+Membership and data by Private Market View
JHM Biopharma valuation
JHM Biopharma's last reported valuation was $160 million in May 2024. No priced round, secondary trade or fund mark has surfaced since.
JHM Biopharma investors
13 investors are on record for JHM Biopharma, including Suzhou Oriza Holdings Corporation, SDIC Unity Capital, Shanghai Guofang Private Equity Fund Management Company and 3E Bioventures Capital.
About JHM Biopharma
Provider and developer of biological proteins used as medications. The company is committed to advancing the application of innovative recombinant protein drugs in endocrinology, neurotherapeutics, skin anti-aging and new-generation biomedical materials, providing breakthrough biomedical products and therapeutic solutions for patients.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- jhm-biopharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.